Shire touts $10B sales target to fend off AbbVie as other suitors circle

Save

Shire has maintained that it's better off alone, rejecting three recent merger bids from AbbVie worth as much as $46.5 billion. Now, it's laying out its case. The Irish drugmaker outlined a plan to double sales by 2020–but that may not be enough to keep predators at bay.